A nurse is reviewing a client's medical history before administering a new prescription for atropine. Which of the following client conditions is contraindicated?

A) Digoxin and levothyroxine: Digoxin is a cardiac glycoside used to treat heart failure and atrial fibrillation, while levothyroxine is a thyroid hormone replacement medication used to treat hypothyroidism. While both medications have potential side effects, hearing loss is not typically associated with either digoxin or levothyroxine. Therefore, monitoring for hearing loss related to a medication interaction is not a priority for clients taking digoxin and levothyroxine.

B) Losartan and atorvastatin: Losartan is an angiotensin II receptor blocker used to treat hypertension, while atorvastatin is a statin medication used to lower cholesterol levels. Hearing loss is not a known side effect of either losartan or atorvastatin, nor is there evidence of an interaction between these medications that would increase the risk of hearing loss. Therefore, monitoring for hearing loss related to a medication interaction is not indicated for clients taking losartan and atorvastatin.

C) Propranolol and raloxifene: Propranolol is a beta-blocker used to treat hypertension, angina, and other cardiovascular conditions, while raloxifene is a selective estrogen receptor modulator used to prevent and treat osteoporosis in postmenopausal women. Neither propranolol nor raloxifene is associated with hearing loss as a common side effect. Additionally, there is no known interaction between propranolol and raloxifene that would increase the risk of hearing loss. Therefore, monitoring for hearing loss related to a medication interaction is not necessary for clients taking propranolol and raloxifene.

D) Furosemide and amikacin: Furosemide is a loop diuretic that is commonly used to treat fluid overload conditions such as heart failure and edema. Amikacin is an aminoglycoside antibiotic used to treat bacterial infections. Both furosemide and amikacin have the potential to cause ototoxicity, which can manifest as hearing loss or tinnitus. When administered concurrently, especially at higher doses or for prolonged durations, the risk of ototoxicity may increase due to additive or synergistic effects on the inner ear structures. Therefore, the nurse should monitor clients receiving both furosemide and amikacin for signs of hearing loss, such as changes in hearing acuity or tinnitus, and promptly report any concerns to the healthcare provider for further evaluation and management.

A) Black stools: While black stools can be a potential side effect of gastrointestinal bleeding, it is not commonly associated with high-dose metoclopramide. This side effect is more commonly seen with medications such as aspirin or NSAIDs. Therefore, it is not the most pertinent adverse effect to monitor for with high-dose metoclopramide.

B) Dry cough: Dry cough is not a typical adverse effect of metoclopramide. Cough is more commonly associated with medications such as ACE inhibitors. Therefore, it is not the primary adverse effect to monitor for with high-dose metoclopramide.

C) Oral candidiasis: While oral candidiasis (oral thrush) can occur as a side effect of some medications, it is not commonly associated with metoclopramide. Oral candidiasis is more frequently seen with corticosteroids or antibiotics. Therefore, it is not the primary adverse effect to monitor for with high-dose metoclopramide.

D) Tardive dyskinesia: Tardive dyskinesia is a serious adverse effect associated with prolonged use of edicaopramide, especially at high doses. It is characterized by involuntary, repetitive movements of the face, tongue, or other parts of the body. Monitoring for signs and symptoms of tardive dyskinesia, such as repetitive facial grimacing or tongue protrusion, is crucial when administering high-dose metoclopramide to prevent this potentially irreversible condition. Therefore, this is the correct adverse effect to monitor for in clients receiving high-dose metoclopramide.